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Effectiveness and Efficacy of Zinc for the Treatment of
Acute Diarrhea in Young Children
Tor Arne Strand, MD*‡; Ram Krisna Chandyo, MD*‡; Rajiv Bahl, MD, PhD§;
Pushpa Raj Sharma, MBBS, DCH, FCPS‡; Ramesh Kant Adhikari, MD‡; Nita Bhandari, PhD§;
Rune Johan Ulvik, MD, PhD¶; Kåre Mølbak, MD, PhD; Maharaj Krishan Bhan, MD§; and
Halvor Sommerfelt, MD, PhD*
ABSTRACT. Intervention trials have shown that zinc is
efficacious in treating acute diarrhea in children of de-
veloping countries. In a randomized, placebo-controlled
trial, we assessed the effectiveness and efficacy of giving
3 Recommended Daily Allowances of elemental zinc to
6- to 35-month-old children with acute diarrhea.
Methods. Seventeen hundred ninety-two cases of
acute diarrhea in Nepalese children were randomized to
4 study groups. Three groups were blinded and the chil-
dren supplemented daily by field workers with placebo
syrup, zinc syrup, or zinc syrup and a massive dose of
vitamin A at enrollment. The fourth group was open and
the caretaker gave the children zinc syrup daily. Day-
wise information on morbidity was obtained by house-
hold visits every fifth day.
Results. The relative hazards for termination of diar-
rhea were 26% (95% confidence interval [CI]: 8%, 46%),
21% (95% CI: 4%, 38%), and 19% (95% CI: 2%, 40%)
higher in the zinc, zinc-vitamin A, and zinc-caretaker
groups, respectively, than in the placebo group. The rel-
ative risks of prolonged diarrhea (duration >7 days) in
these groups were 0.57 (95% CI: 0.38, 0.86), 0.53 (95% CI:
0.35, 0.81), and 0.55 (0.37, 0.84); zinc accordingly reduced
the risk of prolonged diarrhea with 43% to 47%. Five
percent and 5.1% of all syrup administrations were fol-
lowed by regurgitation in the zinc and zinc-vitamin A
group, respectively, whereas this occurred after only 1.3%
of placebo administrations. Vomiting during diarrhea
was also more common in children receiving zinc.
Conclusions. Three Recommended Daily Allowances
of zinc given daily by caretakers or by field workers
substantially reduced the duration of diarrhea. The effect
of zinc was not dependent on or enhanced by concomi-
tant vitamin A administration. Pediatrics 2002;109:898–
903; zinc, vitamin A, acute diarrhea, young children, ran-
domized placebo controlled trial, effectiveness, Nepal,
treatment.
ABBREVIATIONS. RDA, Recommended Daily Allowance.
Intervention trials indicate that zinc given duringacute diarrhea is efficacious in reducing the du-ration and severity of the illness.1–7 Thus, thera-
peutic use of zinc has the potential of reducing the
annual 2.5 million childhood diarrheal deaths.8 A
recent pooled analysis showed a small beneficial ef-
fect of zinc given by health personnel on the risk of
continuation of diarrhea. The overall reduction in the
risk of prolonged diarrhea, defined as an episode
lasting 7 days, was 20% and had a wide confi-
dence interval that included 1.6 The effectiveness of
zinc when given by caretakers has yet to be deter-
mined.
Zinc is involved in the release of vitamin A from
the liver cells,9 in the synthesis of retinol-binding
protein,10 and the effect of zinc in infectious diseases
may be dependent on adequate vitamin A status.10,11
In some of the trials that showed a beneficial impact
of zinc during diarrhea, the participants in the pla-
cebo as well as in the zinc group were given vitamin
A or a micronutrient mixture that included vitamin
A.1–3,6,7 It is possible that, in some of these trials,
the replenishment of vitamin A stores were a prereq-
uisite for the effects of zinc. A recent study from
Bangladesh indicated that zinc and vitamin A sup-
plementation interacted in reducing the prevalence
of persistent diarrhea and dysentery in children.12
However, other studies from Bangladesh failed to
demonstrate an interaction between these 2 micro-
nutrients given during diarrhea.5,13
The effectiveness of zinc administration should be
appropriately investigated before it is recommended
routinely as an adjunct therapy for acute childhood
diarrhea in developing countries. Moreover, an in-
depth evaluation of possible adverse effects of zinc
administration is needed and has been lacking in
reports from previous trials.
In a placebo-controlled trial, we administered 3
Recommended Daily Allowances (RDAs)14 of ele-
mental zinc, which is in the upper range of the doses
given in previous trials. We chose a relatively large
dose because zinc is lost in the stool during diar-
rhea,15 and because of the variable effect of zinc in
previous studies.1–7 The supplement was given daily
by field workers or by caretakers to assess efficacy
and effectiveness, respectively, of zinc on the dura-
tion of acute childhood diarrhea, on the proportion
of episodes that became prolonged, and on stool
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frequency. We also monitored the children for ad-
verse effects. Furthermore, we included a study
group to ensure that the effect of zinc was not re-
stricted to children that were simultaneously supple-
mented with vitamin A.
METHODS
This was a double-blind, randomized, placebo-controlled trial
in children designed to measure the impact of daily zinc admin-
istration with or without a massive vitamin A dose at enrollment
on the duration and severity of acute diarrhea. The effectiveness of
the caretaker giving zinc to the child was assessed in an open
group whereas the 3 other study groups (placebo, zinc, and vita-
min A-zinc) were double-blinded (Fig 1).
The trial had ethical clearance from the Nepalese and Norwe-
gian national health authorities. The implementation of all aspects
of the project was in agreement with the International Ethical
Guidelines for Research Involving Human Subjects as stated in the
latest version of the Helsinki Declaration. Informed and, when
possible, written consent was obtained from at least 1 of the
parents.
Sample Size Calculations
The sample sizes were calculated for 80% power and 95%
confidence. In the calculations we assumed that 20% of the cases
in the placebo group had a duration of 7 days1 and set the
desired percentage of such prolonged episodes in each of the
intervention groups to 12.5 (ie, 37.5% reduction), which resulted in
a required group size of 405. With an expected 10% loss to follow-
up, we decided to enroll 450 episodes in each of the 4 study
groups. The power to detect any superadditive effect of zinc and
vitamin A over zinc alone was lower; this comparison was not an
objective of the trial.
Inclusion and Exclusion Criteria, Definitions, and
Randomization
We enrolled children from the whole municipality of Bhakta-
pur, which is the third largest town in the Kathmandu valley in
Nepal. Children were recruited by weekly household-based sur-
veillance and at spontaneous visits to the study field clinic. Diar-
rhea was defined as the passage of 3 or more loose or watery stools
in the 24-hour period before enrollment. Eligible children were
screened in the clinic by a physician and included if the respon-
sible caretaker was willing to let him/her participate. We included
children between 6 and 35 months that had had diarrhea for 96
hours. Children were allocated to either of the 4 intervention
groups (Fig 1) by simple randomization with blocks of 16.
A child was not included if he or she had received a massive
dose of vitamin A during the previous 4 weeks, had severe illness
requiring hospitalization, or if the family intended to leave Bhak-
tapur within 2 months. We allowed a child to be rerandomized
and enrolled in the study only if 4 months had lapsed from
recovery from the previous enrollment episode.
Recovery from diarrhea was defined as the first of the first 2
consecutive diarrhea-free days. A diarrhea-free day was a day
when the child passed 3 loose and no watery stools.
Interventions, Blinding, and Cointerventions
Vitamin A or placebo administered from identical capsules
were given on the enrollment day, and zinc or placebo syrup were
given daily during diarrhea until 7 days after recovery. The pla-
cebo syrup (1 kg syrup contained 597 g of water, 400 g of sugar,
1.2 g of peach flavor number 061508 [Einar Willumsen, 23–25
Abildager, Brøndby, Denmark], 1 g of methylparabene, 1 g of
xanthan gum, 0.15 g of saccharin sodium) and the zinc syrup were
identical in appearance. The taste and acceptability of the syrup
was assessed in Scandinavian and Indian adults and children
before manufacture. The highest concentration at which the taste
of the placebo and zinc syrups was identical was 2.5 mg of zinc per
mL, although even additional dilution could not mask a minor
metallic aftertaste. We administered 6 and 12 mL of syrup daily to
infants and older children, respectively, to provide 3 RDAs of zinc.
The capsules and syrup with backups were packed in separate
plastic bags, which were assigned a unique serial number before it
was shipped to Nepal. The randomization list that linked the serial
numbers with the group identity was kept at the Statens Serum
Institute in Copenhagen, Denmark, until the end of enrollment
and follow-up. Whether the child belonged to the open “caretaker-
zinc” group or to one of the blinded placebo, zinc, or zinc-vitamin
A groups was not revealed to the study staff until after the child
had been enrolled. This information was kept inside sealed enve-
lopes in the individual plastic bags that were opened only after the
vitamin A or placebo capsules were administered. In the placebo,
zinc, and zinc-vitamin A groups, the syrup was administered
daily by a field worker at home except on public holidays when
the syrup was given by the caretaker, usually the mother. In the
caretaker-zinc group, the caretakers were requested to administer
the zinc syrup every day. Thus, the study staff and the caretakers
in the open “caretaker-zinc” group knew that the children re-
ceived zinc.
Oral rehydration salts packets were given to the mother with
instructions on its mixing and administration, along with standard
messages on feeding. Acute lower respiratory tract infections,
dysentery, anemia, and severe malnutrition were managed ac-
cording to World Health Organization guidelines.16
Fig 1. Profile of a randomized, place-
bo-controlled trial evaluating 3 RDAs
of daily zinc administration as treat-
ment for acute diarrhea in children 6 to
35 months of age.
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Data Collection
Children were weighed at enrollment using a scale with 100 g
sensitivity (Salter, SECA, Germany). A study physician drew
blood from the cubital vein into zinc-free heparinized polypro-
pylene tubes (Sarstedt, Nu¨mbrecht, Germany) at enrollment and
in a 15% random subsample after 14 days. Heparinized blood was
centrifuged, separated, and transferred to zinc-free polypropylene
vials (Eppendorf, Hinz, Germany) and kept frozen until analysis.
The hemoglobin concentration was analyzed with Hemocue (A¨n-
gelholm, Sweden), and cases of anemia were treated with iron
sulfate according to national guidelines. Plasma zinc was deter-
mined by inductively coupled plasma atomic emission spectrom-
etry from Thermo (Jarell-Ash, Franklin, MA), at a wavelength of
206.2 nm.
We examined the child and recorded day-wise information on
morbidity every fifth day until recovery from the diarrhea epi-
sode. At each visit, details of illness characteristics, including the
number and character of stools and vomiting, on each day since
the last visit were obtained, and hydration status was assessed.
Compliance was measured by reported intake and by measur-
ing the remaining volume of syrup in the returned bottles. On a
group level, delivery of zinc was assessed by average change in
plasma zinc concentration from baseline. Field workers observed
and recorded side effects such as regurgitation of the syrup during
the first 15 minutes after administration. In the caretaker-zinc
group, information on compliance, regurgitation, and vomiting
was based on recall and recorded every fifth day on the morbidity
visit. In addition, on the last day of supplementation when chil-
dren were visited for bottle collection, the response to an open
question about other side effects was recorded.
The field workers were trained until they reached the desired
level of intra-observation and interobservation variability for mea-
surement of respiratory rate, body temperature, height, and
weight. They were also trained to memorize the standard mes-
sages to ensure uniformity of the information to the study partic-
ipants. Retraining, standardization, and supervision of the field
staff were done at 5 monthly intervals throughout the data collec-
tion period. Throughout the entire study period, in 8% of all home
visits, supervisors or study physicians supervised the field work-
ers or undertook independent visits, completing the same ques-
tionnaires in addition to a separate form on field worker perfor-
mance. This was done to ensure appropriate interaction between
the participants and the study staff and to maximize data quality.
Data Management and Analysis
The data were double entered into Microsoft VisualFoxPro
databases (Microsoft Corp, Redmond, WA) with computerized
logic, range, and consistency checks. If errors were detected, the
forms were returned to the field for correction the next day.
Weight-for-age, length-for-age, and weight-for-length z scores
were calculated using LMS values17 obtained from Centers for
Disease Control and Prevention growth charts.18 Statistical anal-
yses were undertaken using the statistical, data management
package Stata, version 6 (StataCorp, College Station, TX) and SAS
version 8.1 (SAS Institute, Cary, NC). All analyses were conducted
on an intent-to-treat basis. The identity of the 4 intervention
groups was revealed to the investigators only after the statistical
analyses were completed. Log-transformed counts of the total
number of stools during the first 4 days were compared between
the groups using linear regression, values were antilogged, and
the results were expressed as geometric mean or the ratios of
geometric means compared with the placebo group.
Relative risks were obtained by a generalized linear model with
binomial variability and a logarithmic link function. Comparison
of the number of days from enrollment until recovery was under-
taken using a Cox proportional hazards model with the “discrete”
option in SAS for handling ties. We coded the outcomes and
interventions so that ratios of geometric mean 1, relative risks
1, and hazard ratios 1 would represent a beneficial effect.
Correction for repeated entries of the same child was done by
generalized estimation equations with an exchangeable covari-
ance-variance structure corresponding to a random cluster effect.
RESULTS
Twenty-nine percent of the enrolled children were
stunted and 22% wasted (Table 1). Infants consti-
tuted 41% and there were more boys (55%) than girls.
The residence of the children was evenly distributed
among the 17 administrative areas of Bhaktapur mu-
nicipality. One hundred eighty-five children were
enrolled twice, and 13 were enrolled 3 times.
Almost 10% reported blood in stools before enroll-
ment and, when examined by the study physician,
12% were mildly dehydrated. We had few dropouts,
which were evenly distributed among the study
groups (Fig 1). Of the 14 children lost before recov-
ery, 5 withdrew consent, and 9 migrated out of the
study area.
Baseline characteristics, including the severity of
disease, pre-enrollment duration, child and family
characteristics, and baseline zinc concentrations were
evenly distributed between the intervention groups
(Table 1). More than 95% of the scheduled doses
were reported to be consumed in all 4 groups; this
was confirmed by measuring the remaining syrup on
return of the bottles and reflected in the change in
plasma zinc concentration (Table 2).
The mean duration of diarrhea was shorter and the
proportion with duration more than 3, 7, and 14 days
consistently and substantially lower among the chil-
TABLE 1. Enrollment Characteristics of 4 Groups of Children 6 to 35 Months of Age in a Trial Evaluating 3 RDAs of Daily Zinc
Administration as Treatment for Acute Diarrhea
Variable Study Group
Placebo Zinc Vitamin A-Zinc Caretaker-Zinc
Mean age, mo 15.9 (7.9) 15.3 (7.6) 15.5 (7.8) 15.4 (7.9)
Percentage of infants 39.2 39.8 39.6 43.8
Percentage male gender 54.6 58.8 54.4 53.6
Percentage breastfed 81.4 82.8 83.6 83.7
Total number of stools 24 h before enrollment 8.8 (4.1) 9.0 (4.2) 9.2 (4.5) 8.8 (3.5)
Number of watery stools 24 h before enrollment 3.1 (4.1) 3.0 (4.0) 3.2 (4.2) 2.6 (3.8)
Percentage reporting blood in stool 12.1 10.7 8.4 7.8
Mean number of diarrhea days before enrollment 2.2 (1.2) 2.1 (1.2) 2.2 (1.1) 2.2 (1.1)
Percentage dehydrated 11.9 12.1 10.4 12.1
Percentage less than 2Z length for age (stunted) 29.5 29.1 31.3 27.9
Percentage less than 2Z weight for length (wasted) 23.3 21.5 23.8 20.3
Mean hemoglobin level (g/dL) 11.2 (1.1) 11.1 (1.1) 11.1 (1.3) 11.1 (1.3)
Percentage of mothers who can read 50.0 53.1 45.6 58.1
Percentage of fathers who can read 83.8 88.4 81.0 86.5
Average plasma zinc concentration (mol/dL) 8.6 (1.4) 8.7 (2.2) 8.8 (1.5) 8.7 (1.9)
Standard deviation in parentheses; dehydration defined according to World Health Organization guidelines.
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dren in the zinc, vitamin A-zinc, and caretaker zinc
groups than in the placebo group (Table 2). The
hazard ratios between the placebo group and the
intervention groups were 1.26, 1.21, and 1.19, respec-
tively. The proportion with prolonged diarrhea was
43%, 47%, and 45% lower in these 3 groups (Table 2)
compared with placebo. Only 2.5% of the episodes in
the placebo group lasted 14 days after enrollment.
The effect sizes at this cutoff were similar to what
was seen at day 7, but with wider confidence inter-
vals, which included 1 (Table 2).
Daily average stool frequency during the first 4
days after enrollment was marginally lower in chil-
dren that received zinc (Table 2). The proportion of
cases with watery diarrhea after enrollment in the
children receiving zinc was not substantially or sig-
nificantly different from those receiving placebo (Ta-
ble 2).
There was no difference among the 3 groups of
children that received zinc in the severity, as mea-
sured by stool frequency, or in the duration of diar-
rhea (Table 2).
Other Effects
A higher proportion of syrup administrations was
followed by regurgitation in the children receiving
zinc than in those receiving placebo (Table 3). In the
placebo group, 1.3% of the administrations were fol-
lowed by regurgitation while this percentage was
5.0%, 5.1%, and 7.3% in the zinc, vitamin A-zinc, and
caretaker zinc groups, respectively. The figures in
Table 3 give the percentage with regurgitation on the
first day and on the subsequent days separately.
Approximately one third of these regurgitations oc-
curred on the enrollment day regardless of group
identity. The excess regurgitation in children given
zinc was similar in the different age groups (Table 3).
The total vomiting beyond the 15 minutes after syrup
administration was also higher in the children re-
ceiving zinc (Table 3).
An open question asked on the last day of supple-
mentation revealed no other side effects than vomit-
ing or regurgitation, nor were any such adverse
events observed during the intervention period. The
change in plasma copper was the same in children
receiving zinc as in children receiving placebo (Table
2).
Eight hundred thirty-two of the enrolled children
made 1209 visits to the field clinic; the number of
visits and the number of children who visited the
field clinic were similar among the intervention
groups. Likewise, there were no differences in care-
taker-reported morbidity, the number of physician
visits, or hospitalizations during the 1-month period
after recovery from the diarrhea episode.
DISCUSSION
Our data show a substantial and highly significant
beneficial effect of zinc on the duration of diarrhea in
children between 6 and 35 months of age. We en-
rolled children from an entire Nepalese urban area,
and the recruitment was not restricted to a slum or to
selected patient groups. This is in contrast to previ-
ous reports where inclusions were limited to lower
socioeconomic strata, hospitalized, or to malnour-
ished children.1–7 The overall effect size in the
present study was larger than what has previously
been reported. Thus, in our study, zinc resulted in a
43% to 47% reduction in the risk of prolonged diar-
rhea. This impact is similar to what was found in the
subgroup of children enrolled by day 3 after onset of
diarrhea in a trial in a New Delhi slum.1 We included
only children who had had diarrhea for 4 days or
less, suggesting that zinc is more effective when
given early in the course of the illness.
Although we demonstrated a reduction in daily
total stool frequencies, this effect was of much
smaller magnitude than that on duration. The most
important effect of zinc is probably to prevent a
nutritional insult caused by persistence of the epi-
TABLE 2. Main Outcomes in a Trial Evaluating 3 RDAs of Daily Zinc Administration as Treatment for Acute Diarrhea in Children
6 to 35 Months of Age
Variable Study Group
Placebo Zinc Vitamin A-Zinc Caretaker-Zinc
Duration of supplementation (d) 10.6 9.9 10.0 10.0
Percent of days with scheduled syrup
administration
98.2 97.6 97.1 95.8
Average daily zinc ingested by the infants
(mg/kg/d)
0 1.9 1.9 1.9
Average daily zinc ingested by other children
(mg/kg/d)
0 3.1 3.1 3.1
Mean plasma zinc (mol/dL) change (SD)* 0.2 (2.1) 3.7 (5.9) 4.6 (8.0) 2.7 (4.7)
Mean plasma copper (mol/dL) change (SD)* 1.5 (4.2) 1.1 (5.5) 1.4 (4.1) 1.8 (4.5)
Relative hazard (time to recovery) 1 1.26 (1.08,1.46) 1.21 (1.04,1.38) 1.19 (1.02,1.40)
Risk Ratios or Ratios of Geometric Mean
Compared With Placebo (95% CI)
Cases (%) with postenrollment duration 3 d 159 (35.7) 0.75 (0.61,0.91) 0.83 (0.68,1.00) 0.80 (0.66,0.97)
Cases (%) with postenrollment duration 7 d 58 (13.1) 0.57 (0.38,0.86) 0.53 (0.35,0.81) 0.55 (0.37,0.84)
Cases (%) with postenrollment duration 14 d 11 (2.5) 0.55 (0.20,1.47) 0.64 (0.25,1.63) 0.64 (0.25,1.63)
Cases (%) with postenrollment watery diarrhea 167 (37.6) 0.91 (0.76,1.08) 0.90 (0.76,1.08) 1.03 (0.87,1.21)
Geometric mean number of stools first 4 d
(95% CI)
13.9 (13.2,14.6) 0.91 (0.85,0.97) 0.95 (0.89,1.02) 0.93 (0.87,1.00)
SD indicates standard deviation; CI, confidence interval.
* Change from enrollment until 14 days thereafter.
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sode and not to reduce the risk of severe dehydra-
tion,19 and should therefore be considered as an im-
portant addition to oral rehydration therapy.
This trial demonstrates that zinc is as effective in
treating diarrhea when given daily by the caretaker
as when given by trained field workers. In our pop-
ulation, the effect was not restricted to children who
were also given vitamin A, nor was it enhanced by
vitamin A administration at enrollment, although the
power to identify the latter was limited. This indi-
cates that zinc exerts its beneficial effect indepen-
dently of vitamin A. Indeed, the results from studies
of the effect of vitamin A on the recovery from acute
diarrhea are conflicting.11,20–22
The compliance in the caretaker zinc (effective-
ness) group may have been reinforced by the mor-
bidity visits. However, the field workers were re-
quested to restrain from message delivery during
these visits and the effectiveness of zinc was evident
already on the third day after enrollment (Table 2),
ie, even before the first morbidity visit.
Zinc-supplemented children experienced more re-
gurgitation and vomiting than did children who re-
ceived placebo. Regurgitation and vomiting have not
previously been reported as a side effect of zinc
when treating diarrhea. Our findings may be attrib-
utable to the fact that our dose was relatively high
compared with many other trials, and that in some of
these trials, the daily dose was divided.3,4,7 On the
other hand, it could also be a reflection of more
careful monitoring, as adverse effects were one of the
study outcomes. One third of the regurgitation after
syrup ingestion occurred on the first day. In addition
to the fact that the children may have been somewhat
stressed in the field clinic, a more careful dispensing
by the field workers or caretakers or gastrointestinal
adaptation to zinc may explain the lower regurgita-
tion frequency on the subsequent days. The observed
regurgitation and vomiting did apparently not inter-
fere with the oral rehydration therapy, nor was zinc
supplementation associated with dehydration (data
not shown). If zinc is to be used routinely in acute
diarrhea, adjustment or division of the daily dose, or
perhaps mixing zinc with the oral rehydration salts
solution, could increase acceptance and thereby se-
cure a high effectiveness under program conditions.
Other trials suggest that a lower daily zinc dose may
be almost as efficacious1,3,5 with seemingly no excess
vomiting or regurgitation, although the registration
of side effects may have been less rigorous than in
our study. Therefore, a daily dose of 2 RDAs may be
advisable. Copper status may be affected by zinc
administration15; plasma copper levels were not in-
fluenced by the short term therapeutic zinc admin-
istration of our study.
We were not able to demonstrate any differences
in morbidity among the study groups during the
1-month follow-up period after recovery. Thus, any
beneficial effect of zinc supplementation beyond the
episode was not identified, nor did we reveal any
increased morbidity in the children who received
zinc.
No other treatment has been proven as efficacious
as zinc in reducing the duration of acute diarrhea in
children of developing countries. Antibiotics, anti-
parasitic, antimotility, and antisecretory drugs and
gastric enzymes are overused. Zinc is efficacious
and, in this trial, despite some increase in regurgita-
tion and vomiting, effective and safe in the treatment
of diarrhea. If promoted as an integral part of the
routine management of acute diarrhea instead of the
above mentioned inefficacious and potentially harm-
ful remedies, the promotion of oral rehydration ther-
apy may be strengthened and the spread of antibiotic
TABLE 3. Regurgitation of Syrup and Vomiting Among Children 6 to 35 Months of Age in a Trial Evaluating 3 RDAs of Daily Zinc
Administration as Treatment for Acute Diarrhea
Variable Study Group
Placebo Zinc Vitamin
A-Zinc
Caretaker-
Zinc
Percentage of children with syrup regurgitation
on enrollment day
6.1* 18.6* 21.0* 24.4
Risk ratios (95% CI) 1 3.1 (2.0,4.7) 3.6 (2.4,5.4) 4.0 (2.7,6.0)
Infants 4.6 16.9 20.9 23.6
Risk ratios (95% CI) 1 3.7 (1.7,7.8) 4.6 (2.2,9.5) 5.2 (2.5,10.6)
Older than 12 mo 7.0 19.7 21.1 25.1
Risk ratios (95% CI) 1 2.8 (1.7,4.6) 3.0 (1.8,4.9) 3.6 (2.2,5.8)
Percentage of days with syrup regurgitation
after inclusion day
0.9* 3.8* 3.8* 5.8
Risk ratios (95% CI) 1 4.3 (2.8,6.6) 4.0 (3.1,5.1) 5.6 (4.4,7.2)
Infants 1.0 3.9 4.1 6.2
Risk ratios (95% CI) 1 3.9 (2.5,6.1) 4.0 (2.6,6.34) 6.1 (4.0,9.4)
Older than 12 mo 0.8 3.7 3.6 5.5
Risk ratios (95% CI) 1 4.4 (2.9,6.7) 4.3 (2.8,6.5) 6.6 (4.4,9.9)
Percentage of children with reported vomiting
on enrollment day
18.9 32.7 37.1 38.8
Risk ratios (95% CI) 1 1.7 (1.4,2.2) 2.0 (1.6,2.5) 2.1 (1.6,2.6)
Percentage of days during diarrhea with
vomiting after enrollment day
8.7 16.0 17.3 17.9
Risk ratios (95% CI) 1 1.8 (1.42,2.45) 2.0 (1.6,2.6) 2.0 (1.5,2.6)
CI indicates confidence interval.
* Children were observed for regurgitation and other adverse effects for 15 minutes after a field worker had given the zinc or the placebo
syrup.
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resistance limited. A substantial proportion of diar-
rheal deaths occur in prolonged diarrhea.19,23 De-
creasing the occurrence of prolonged and persistent
diarrhea by zinc administration may substantially
reduce the number of childhood diarrhea deaths.
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CELL PHONES AND WAR IN THE CONGO
“Few owners on mobile phones realize that their technical gadgets may link
them to one of the deadliest of contemporary wars—the conflict in the Democratic
Republic of Congo. COLTAN, short for Columbite-Tantalite, is one of the raw
materials that warring factions have battled over . . . Tantalum is crucial for the
manufacture of capacitors, tiny components that regulate the flow of current on
circuit boards. As one journalist put it, ‘for the high-tech industry, tantalum is
magic dust.’”
Vick K. Vital ore funds Congo’s war. Washington Post. March 19, 2001
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